Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter

Anke Pape(Klinikum Region Hannover), R. Brunkhorst(Klinikum Region Hannover), Jan T. Kielstein(Klinikum Braunschweig), Tillman Krüger(Klinikum Region Hannover), Thomas Fühner(Klinikum Region Hannover)

TH Open

April 1, 2021

10.1055/s-0041-1727121

Cited by 19

Related Papers

Epidemiology of sepsis in Germany: results from a national prospective multicenter study

|Intensive Care Medicine|2007|623

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

|BMJ|2012|309

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

|Journal of the American Society of Nephrology|2002|274

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study

|Arthritis & Rheumatism|1998|261

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry

|Nephrology Dialysis Transplantation|2012|239